Eugenia Uniflora Active Fraction Inhibits Dalton Lymphoma Ascites in Swiss Albino Mice - An in Vivo Study

Abstract

Cancer is one of the major leading causes of death. The cancer cells attack and demolish normal cells. The present study was designed to evaluate the anticancer activity of Eugenia uniflora active fraction (EF18) against Dalton lymphoma ascites tumor model. Eugenia uniflora active fraction was obtained from the partial purification of crude ethanolic extract of Eugenia uniflora and bioassay graded screening of the fractions obtained. In vitro cytotoxicity studies were conducted using short term trypan blue method. For the In vivo anti-cancer study in Dalton's lymphoma ascites, two doses of Eugenia uniflora active fraction 500mg/kg and 250mg/kg were taken. The doses were selected on the basis of acute toxicity studies. The anti-cancer activity was assessed by monitoring the tumor volume, percentage survival time, LDH (Lactate dehydrogenase enzyme) level and histopathological analysis. The standard drug used for In vivo study was Cyclophosphamide. This Cyclophosphamide is mainly used to treat a wide spectrum of cancers. In vitro studies showed that Eugenia uniflora active fraction exhibited cytotoxic activity. The results of the present in vivo study demonstrated that Eugenia uniflora active fraction, especially its higher dose (500mg/kg) was better in reducing the tumor volume, increasing the percentage life span and lowering the LDH level when compared to the lower dose. The histopathological analysis also supported that Eugenia uniflora active fraction possessed anti-cancer activity. The outcome of the entire study showed that the higher dose of EF 18 was better than the lower dose.